Antibiotic Resistance: Advancing Infectious Disease Therapeutics for Patients

Significance of the proposed special issue:

Over the past four decades, the United States Congress has enacted legislation aimed at providing various incentives to promote the development and regulatory approval of antibiotics. These legislative acts include the Food and Drug Administration Modernization Act (1997), the Generating Antibiotic Incentives Now Act (2012), the Qualified Infectious Disease Product Designation (2012), and the 21st Century Cures Act (2016). The purpose of these incentives was to address the pressing need for more effective treatment options for patients who lacked viable alternatives. In light of the significant public health risk posed by antibiotic resistance and the growing concerns regarding the emergence of multi-resistant bacterial pathogens, there is an urgent need for the discovery and research of novel antibiotics and research in this area. Therefore, this Special Issue will shed light on the effectiveness of US regulatory measures and implemented policies in bringing novel systemic antibiotics to the US market compared to available therapeutic alternatives addressing unmet medical needs for drug-resistant bacteria.

Call for papers for Special Issue on :

Dear Colleagues,

This Special Issue of Healthcare is dedicated to addressing the crucial challenge of developing novel antibiotics that can effectively tackle drug resistance, enhance patient outcomes, and meet unmet medical needs.

Federal regulation enacted since the early 1990s, including the Prescription Drug User Fee Act (1992), the Food and Drug Administration Modernization Act (1997), the Generating Antibiotic Incentives Now Act (2012), and the Qualified Infectious Disease Product Designation (2012), and the 21st Century Cures Act (2016), was aimed at accelerating drug development to bring more efficacious drugs to the US market faster. As antibiotic resistance continues to undermine the effectiveness of antibiotics and concerns surrounding multi-resistant bacterial pathogens intensify, there is a pressing need for robust research on the added value of antibiotics addressing the need for the greater effectiveness of new antibiotics in patients who lack effective options. This Special Issue focuses on exploring the multifaceted factors that have contributed to the existing crisis in the development of novel antibiotics. Furthermore, it aims to provide managers, policymakers, and other stakeholders with up-to-date knowledge and valuable insights into the impact of regulation and policy, clinical practices, and patient-centered outcomes on the development of innovative antibiotics for patients with susceptible and resistant pathogens who lack effective options to enhance their survival, improve functioning, and reduce their symptoms burden.

This Special Issue will consider original articles, with a special focus on issues such as:

1. Antibiotic resistance;
2. Regulation and policy in clinical practice;
3. Standards and evidence for approval of anti-infectives;
4. Utilization management, empirical use, and appropriate prescribing of antibiotics;
5. Comparative effectiveness and patient outcomes;
6. Antibiotics pricing and reimbursement.

All manuscripts submitted to this Special Issue will undergo a rigorous peer-review process.

Dr. Rosa Rodriguez-Monguio
Prof. Dr. Enrique Seoane-Vazquez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• antibiotic resistance
• regulation and policy in clinical practice
• standards and evidence for approval of anti-infectives
• utilization management, empirical use, and appropriate prescribing of antibiotics
• comparative effectiveness and patient outcomes
• antibiotics pricing and reimbursement